Genmab — December 2018

[bibob]

Maybe Genmab have the needle.

[Sukkeralf]

Jan said Its because Its so hard to predict what you exactly need - three is better than one

[Sukkeralf]

But nice data for BsAbs will give more value to Genmabs preclinical and early pipeline as it based on this

[Solsen]

Discontinuation was relative high in Regenerons trial. The silencing of the CD3 arm could be the right way

[Bulder]

Just a detail: It's not the cd3-arm that is silenced. It's the Fc-part.

[Solsen]

Correct

[Solsen]

The data presented at ASH included a total of 68 patients with R/R B-NHL who were treated with REGN1979. These patients had received a median of three prior therapies, including an anti-CD20 therapy. As of September 2018, 14 patients had completed treatment, 13 patients remained on treatment and 41 had discontinued treatment. The most common reason for treatment discontinuation was progressive disease (27 patients).

[Solsen]

2/3 of pts discontinued !

[E_L]

https://twitter.com/DrOmarNadeem/status/1068937605721448448

[E_L]

on Griffin https://twitter.com/akeithstewart/status/1068961191349764096

[peter12]

Hvordan kan de skrive 100% ORR når 66% stopper ?

[E_L]

JNJ news release https://www.prnewswire.com/news-releases/darzalex-daratumumab-combination-regimens-show-positive-results-for-newly-diagnosed-and-relapsed-patients-with-multiple-myeloma-300758631.html

[Solsen]

Griffin are outstanding

[Solsen]

Ny måde at rapportere på peter12. AMG-420 resultater blev rapporteret tilsvarende. Men hvem mon de vil snyde ?

[Bulder]

@ peter12: Jeg kan ikke se andet end at pts trods alt responderer, men relapser kort efter alligevel.

[Bulder]

HR på pfs i Alcyone faldet fra 0,5 til 0,43!

[Solsen]

Kan du læse det bulder. Synes at sådanne meddelelser er vanvittig dårlige (Regeneron)

[Solsen]

Super og hvad vi ventede omkring HR.

[Solsen]

Jeg er ikke sikker på, at de tæller pts med når de "discontinue"

[Plimsoller]

Efter den pressemeddelelse, er der overhovedet noget tilbage til præsentationen i morgen?